A peer-reviewed study finds the company’s telehealth-guided pathway for mandibular advancement devices achieved significant apnea-hypopnea index reductions and high treatment success rates.
Read More
The company’s narcolepsy treatment shows strong growth, while its late-stage pipeline advances with five phase 3 trials and a novel orexin agonist.
Read More
The deal will bring the narcolepsy treatment LUMRYZ under the Alkermes portfolio.
Read More
A new KPAP vs CPAP clinical study challenges long‑held assumptions about continuous airway pressure. This practitioner‑focused summary explores how pressure timing impacts comfort and therapy experience without compromising efficacy. Designed for sleep medicine professionals, the brief highlights key findings, patient preference data, and clinical considerations drawn from peer‑reviewed research.
Read More
The new assessment-based certificate is designed for experienced sleep professionals who manage patients with complex sleep therapy needs.
Read More